Bortiva 3.5mg Injection belongs to a group of anti-cancer medicines used to treat adult patients with multiple myeloma and mantle cell lymphoma who have received at least one prior therapy. Multiple myeloma, also known as myeloma, is a type of bone marrow cancer it affects several areas of the body, such as the spine, skull, pelvis, and ribs. Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma (NHL). It develops when B-cells (also called B-lymphocytes) become abnormal. B-cells are white blood cells that fight infection.

Bortiva 3.5mg Injection contains 'Bortezomibx' that works by interfering with how proteasomes work, which may cause cancer cells to die and may stop cancer from growing and eventually kills them.

Bortiva 3.5mg Injection is prescribed by a doctor experienced in the use of medications to treat cancer. It is administered by a healthcare professional as an injection into your vein (intravenously or IV) or under your skin (subcutaneously or SC). Bortiva 3.5mg Injection must not be administered into your spinal fluid (intrathecally). You may experience nausea, diarrhoea, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), peripheral neuropathy (nerves malfunction), fatigue, neuralgia, anaemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia. Most of these side effects of Bortiva 3.5mg Injection do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor.

To treat your condition effectually, continue taking Bortiva 3.5mg Injection for as long as your doctor has prescribed. Do not stop the Bortiva 3.5mg Injection midway. Talk to your doctor before taking Bortiva 3.5mg Injection if you have allergies or if you are suffering from peripheral neuropathy (nerves malfunction), hypotension, cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), hepatic disorders. Avoid taking Bortiva 3.5mg Injection if you are pregnant or breastfeeding because this Bortiva 3.5mg Injection can cause harmful effects on the unborn baby. Both women and men using this Bortiva 3.5mg Injection should use birth control to avoid pregnancy.

Bortiva 3.5mg Injection contains the active substance bortezomib, also-called ‘proteasome inhibitor. Proteasomes play an important role in controlling cell function and growth. By interfering with their function, thereby it can kill cancer cells. Bortiva 3.5mg Injection is used to treat multiple myeloma (a cancer of the bone marrow) and mantle cell lymphoma (a type of cancer affecting the lymph nodes) in 18 years or older patients. It can be used alone or together with other medicines.

To treat your condition effectually, continue taking Bortiva 3.5mg Injection for as long as your doctor has prescribed. Do not stop the Bortiva 3.5mg Injection midway. Talk to your doctor before taking Bortiva 3.5mg Injection if you have allergies or if you are suffering from peripheral neuropathy (nerves malfunction), hypotension, cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), hepatic disorders. And also, inform your doctor if you have diabetes because this medicine can affect your blood glucose levels. Your doctor may require close monitoring of your blood glucose levels and change your diabetes medicine dose while being treated with Bortiva 3.5mg Injection. Avoid taking Bortiva 3.5mg Injection if you are pregnant because this Bortiva 3.5mg Injection can cause harmful effects on the unborn baby. Both women and men using this Bortiva 3.5mg Injection should use birth control to avoid pregnancy and for at least six months following treatment. Do not breastfeed during treatment with Bortiva 3.5mg Injection and four months after your final dose of Bortiva 3.5mg Injection.

• Bortiva 3.5mg Injection should be taken under strict medical supervision. The doctor will regularly monitor your condition while taking Bortiva 3.5mg Injection.
• Your doctor may get routine blood tests done to monitor your liver function, electrolyte levels, blood cell count in your blood.
• Avoid unnecessary or prolonged exposure to sunlight and UV light (such as tanning booths) and wear protective clothing, sunglasses, and sunscreen. Bortiva 3.5mg Injection may make your skin sensitive to sunlight.